EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)

Jialing Lin, Sallie-Anne Pearson, Jerry R Greenfield, Kyeong Hye Park, Alys Havard, David Brieger, Richard O Day, Michael O Falster, Juliana de Oliveira Costa

European Journal of Clinical Pharmacology · 2023-09 · 79 (9) · 1239-1248

DOI: 10.1007/s00228-023-03539-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 14.07.2023. Verfasst von Jialing Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australi…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Symporters. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NHMRC Medicines Intelligence Centre of Research Excellence, National Health and Medical Research Council (NHMRC) Ideas Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate trends in SGLT2i and GLP-1RA use in Australia in the era of increased evidence of their cardiovascular benefits.

Methods

We used national dispensing claims for a 10% random sample of Australians to estimate the number of prevalent and new users (no dispensing in the prior year) of SGLT2i or GLP-1RA per month from January 2014 to July 2022. We assessed prescriber specialty and prior use of other antidiabetic and cardiovascular medicines as a proxy for evidence of type 2 diabetes (T2D) and cardiovascular conditions, respectively.

Results

We found a large increase in the number of prevalent users (216-fold for SGLT2i; 11-fold for GLP-1RA); in July 2022 approximately 250,000 Australians were dispensed SGLT2i and 120,000 GLP-1RA. Most new users of SGLT2i or GLP-1RA had evidence of both T2D and cardiovascular conditions, although from 2022 onwards, approximately one in five new users of SGLT2i did not have T2D. The proportion of new users initiating SGLT2i by cardiologists increased after 2021, reaching 10.0% of initiations in July 2022. Among new users with evidence of cardiovascular conditions, empagliflozin was the most commonly prescribed SGLT2i, while dulaglutide or semaglutide was the most common GLP-1RA.

Conclusion

SGLT2i and GLP-1RA use is increasing in Australia, particularly in populations with higher cardiovascular risk. The increased use of SGLT2i among people without evidence of T2D suggests that best-evidence medicines are adopted in Australia across specialties, aligning with new evidence and expanding indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Cardiovascular DiseasesSymportersHumansAustraliaHypoglycemic AgentsGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Cardiovascular diseaseGlucagon-like peptide-1 receptor agonistsPharmacoepidemiologySodium-glucose co-transporter 2 inhibitorsTrendsType 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSymportersGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. jialing.lin@unsw.edu.au.
  • Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
  • Department of Diabetes and Endocrinology, St Vincent's Hospital, Darlinghurst, Australia.
  • St Vincent's Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
  • Clinical Diabetes, Appetite and Metabolism, Garvan Institute of Medical Research, Darlinghurst, Australia.
  • Endocrinology and Metabolism, National Health Insurance Ilsan Hospital, Goyang-shi, Gyeonggi-do, South Korea.

Förderung

  • Wellcome Trust
  • NHMRC Medicines Intelligence Centre of Research Excellence
  • National Health and Medical Research Council (NHMRC) Ideas Grants
  • National Heart Foundation of Australia
  • University of New South Wales

Zitieren

APA

Lin, J., Pearson, S. A., Greenfield, J. R., Park, K. H., Havard, A., Brieger, D., Day, R. O., Falster, M. O., & de Oliveira Costa, J. (2023). Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022). European Journal of Clinical Pharmacology, 79(9), 1239-1248. https://doi.org/10.1007/s00228-023-03539-8

Vancouver

Lin J, Pearson SA, Greenfield JR, Park KH, Havard A, Brieger D, et al. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022). European Journal of Clinical Pharmacology. 2023;79(9):1239-1248. doi:10.1007/s00228-023-03539-8

BibTeX
@article{Lin2023,
  author = {Lin, Jialing and Pearson, Sallie-Anne and Greenfield, Jerry R and Park, Kyeong Hye and Havard, Alys and Brieger, David and Day, Richard O and Falster, Michael O and de Oliveira Costa, Juliana},
  title = {Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)},
  journal = {European Journal of Clinical Pharmacology},
  year = {2023},
  volume = {79},
  number = {9},
  pages = {1239--1248},
  doi = {10.1007/s00228-023-03539-8}
}
Kostenlos starten →